Summary Ipsen will acquire Memo Therapeutics for up to EUR700M including EUR200M upfront, adding potravitug, a Phase 2 monoclonal antibody for BK polyomavirus-associated nephropathy in kidney transplant recipients. What Happened The acquisition strengthens Ipsen’s rare disease portfolio and supports a…
Summary Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront plus up to $1.3 billion in regulatory and commercial milestones, creating a total potential transaction value of $1.75 billion. The acquisition gives Ipsen control of navtemadlin (KRT-232), an oral…
Summary RQ Bio announced the successful completion of an oversubscribed $115 million Series A financing, led by Frazier Life Sciences, to advance its long-acting antibody platform for influenza prevention. The financing will support IND-enabling development of RQB01, a next-generation monoclonal…
Summary ADC Therapeutics announced a strategic reorganization that will reduce its workforce by approximately 17%, with resources redirected toward Zynlonta growth opportunities and regulatory priorities. The move follows safety concerns in LOTIS-5 and represents a meaningful negative signal for the…
Summary SonoThera closed an oversubscribed $125M Series B financing to advance DMD and ADPKD programs toward the clinic, validating its non-viral genetic medicine delivery platform. What Happened Vida Ventures led the round with participation from ARK Invest, Otsuka, UCB Ventures,…
Summary GSK agreed to acquire Nuvalent for approximately $10.6 billion, one of the largest biotech acquisitions of 2026. The transaction adds late-stage ROS1 and ALK targeted oncology assets and significantly accelerates GSK’s effort to rebuild a leading precision oncology franchise.…
Summary Incyte agreed to acquire Vega Therapeutics for up to $2.0 billion, adding Phase 3 asset VGA039, a first-in-class Protein S-modulating antibody for von Willebrand disease. The deal represents Incyte’s most significant strategic move beyond the Jakafi franchise and positions…
Summary Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology. What Happened Roche will co-develop and co-commercialize bexobrutideg, an oral degrader that eliminates BTK protein rather than inhibiting it. Deep Analysis…
Summary Eli Lilly signed a collaboration with Ascidian worth up to $1.9B to develop in vivo RNA exon-editing therapies for inherited kidney diseases, validating RNA exon editing as a major emerging genetic medicine modality. What Happened The platform uses a…
Summary YolTech Therapeutics raised $70M in a Series C financing to expand what is currently one of China’s most advanced in vivo CRISPR and base-editing platforms, with programs spanning sickle cell disease, beta-thalassemia, ATTR, familial hypercholesterolemia, and primary hyperoxaluria type…
